Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03508609 · ClinicalTrials.gov registry record · Phase 2

Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

A Phase 2 study of Coronary Microvascular Dysfunction, sponsored by Lisata Therapeutics.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
2
Study locations

NCT03508609 is a Phase 2 study of Coronary Microvascular Dysfunction that has completed, run by Lisata Therapeutics. The registered enrollment target is 20 participants, below the 269-participant average among 7 other Coronary Microvascular Dysfunction trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03508609, a Phase 2 study of Coronary Microvascular Dysfunction, has completed, sponsored by Lisata Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single intracoronary infusion of CLBS16.

Conditions Studied

Coronary Microvascular Dysfunction

Interventions

  • BIOLOGICAL CLBS16

Study Locations (2)

California

  • Cedars-Sinai Medical Center - Los Angeles

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-04-19
Est. Completion 2020-05-05
Phase Phase 2

Sponsor

Lisata Therapeutics

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03508609

The ClinicalTrials.gov registry entry for NCT03508609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 269-participant average among 7 other Coronary Microvascular Dysfunction trials with a reported enrollment target (93% lower). The listed sponsor is Lisata Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Microvascular Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which CLBS16 is the first listed.

NCT03508609 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Minnesota.

Frequently Asked Questions

What is clinical trial NCT03508609 about?

NCT03508609 is a clinical study titled "Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease". This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single intracoronary infusion of CLBS16.

What is the current status of trial NCT03508609?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-04-19. Estimated completion is 2020-05-05.

What conditions does trial NCT03508609 study?

This clinical trial studies the following conditions: Coronary Microvascular Dysfunction.

What interventions are being tested in trial NCT03508609?

The interventions under investigation include: CLBS16 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03508609?

This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03508609 being conducted?

This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Microvascular Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Microvascular Dysfunction

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.